Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 27th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.37 per share and revenue of $39.03 million for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.
Ligand Pharmaceuticals Stock Down 1.2 %
LGND stock traded down $1.45 during midday trading on Friday, reaching $120.56. 136,713 shares of the company's stock traded hands, compared to its average volume of 87,456. The company has a 50-day simple moving average of $114.13 and a two-hundred day simple moving average of $110.47. Ligand Pharmaceuticals has a 1-year low of $67.72 and a 1-year high of $129.90. The company has a market cap of $2.28 billion, a price-to-earnings ratio of 48.03 and a beta of 1.04.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the company. Royal Bank of Canada lifted their price objective on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an "outperform" rating in a research note on Wednesday, December 11th. HC Wainwright reiterated a "buy" rating on shares of Ligand Pharmaceuticals in a report on Wednesday, December 11th. Benchmark reiterated a "buy" rating and set a $135.00 target price on shares of Ligand Pharmaceuticals in a report on Monday, December 23rd. Oppenheimer lifted their target price on Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. Finally, Barclays lifted their target price on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an "overweight" rating in a report on Monday, December 16th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $147.00.
Read Our Latest Stock Report on LGND
Insider Activity
In related news, CFO Octavio Espinoza sold 2,104 shares of Ligand Pharmaceuticals stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $116.37, for a total value of $244,842.48. Following the sale, the chief financial officer now owns 20,647 shares of the company's stock, valued at approximately $2,402,691.39. The trade was a 9.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John L. Lamattina sold 2,406 shares of Ligand Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $123.65, for a total value of $297,501.90. Following the completion of the sale, the director now directly owns 29,515 shares in the company, valued at approximately $3,649,529.75. This represents a 7.54 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.
Ligand Pharmaceuticals Company Profile
(
Get Free Report)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
Further Reading

Before you consider Ligand Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.
While Ligand Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.